When it comes to politics, Americans don’t agree on much these days, but they do agree that they don’t like Congress. Just 16% of Americans approve of the job Congress is doing, according to a June Gallup poll, continuing a trend of low approval ratings for the legislative body. That may be for good reason. From repeated battles for the House speakership to threats of government shutdowns, the current Congress has been, in historic terms, more dysfunctional. Our guest today is Jeffery Jenkins, Provost Professor of Public Policy, Political Science and Law for the USC Price School. Jenkins literally wrote the book on contested speakership elections, co-authoring Fighting for the Speakership: The House and the Rise of Party Government. We discuss why this Congress is so dysfunctional, what’s driving increased polarization in U.S. politics and how Congressional Democrats are handling concerns over President Joe Biden’s age.

Thank you to all of our listeners for tuning into the podcast this year. We’re taking a short break this summer to record new conversations that explore the impact of public policy with USC Price School faculty. In the meantime, here are some highlights from our first season, where our guests offered evidence-based insights that paint a more nuanced picture of timely news topics – like policing, political polling and COVID-19 policies.

Four years ago, Elizabeth Currid-Halkett received some of the worst news imaginable: her son, Eliot, was diagnosed with a fatal neuromuscular disease. In her quest to save her son, she learned of a gene therapy that ultimately helped Eliot, but she ran into roadblocks that made it difficult to access this life changing treatment. Her story, recently published in The New York Times, illustrates the obstacles that prevent some patients from obtaining rare disease treatments. In this episode, we are joined by Currid-Halkett, a USC Price School professor of public policy, and Alice Chen, an associate professor of public policy who recently testified before Congress about making rare disease treatments accessible.